Suzuki F, Kuroda T, Tamura T, Sato S, Ohmori K, Ichikawa S
Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Company, Ltd., Shizuoka, Japan.
J Med Chem. 1992 Jul 24;35(15):2863-70. doi: 10.1021/jm00093a020.
We previously described new antiinflammatory agents, 4-hydroxy-2-oxo-1-phenyl-1H-1,8-naphthyridine-3-carboxamides 1. Further modification of the compounds bearing 1-phenyl-1,8-naphthyridin-2-one as a mother skeleton led to 5-phenylimidazo[4,5-c][1,8]naphthyridin-4(5H)-one derivatives 2 and 3. Regioselective synthesis of these compounds bearing a substituent at the 1- or 3-position was conducted according to the method shown in Schemes I and II. In this series of compounds, antiinflammatory activities were greatly influenced by the position and nature of substituents on imidazole. 3-Alkyl or 3-benzyl substitution result in the potent activity, but 1-substitution did not. Minor modification of the benzyl group reduced or eliminated the activity. Detailed examination of structure-activity relationships led to 3-benzyl-5-phenyl-3H-imidazo[4,5-c][1,8]naphthyridin-4(5H)-one (22), which exhibited potent oral antiinflammatory activities in carrageenan-, zymosan-, and reversed passive Arthus reaction-induced rat paw edemas (ED40 = 5.3, 0.37 mg/kg, ED50 = 0.47 mg/kg, respectively). This broad activity of 22 was like that of glucocorticoids. Compound 22 did not affect activities of CO and 5-LO enzymes and receptor binding of various ligands. As one of the mechanisms of action, induction of release of glucocorticoids was postulated. These results suggest that 22 represents a novel class of antiinflammatory agents.
我们之前描述了新型抗炎剂4-羟基-2-氧代-1-苯基-1H-1,8-萘啶-3-甲酰胺1。以1-苯基-1,8-萘啶-2-酮为母核的化合物的进一步修饰产生了5-苯基咪唑并[4,5-c][1,8]萘啶-4(5H)-酮衍生物2和3。根据方案I和II所示的方法进行了在1-或3-位带有取代基的这些化合物的区域选择性合成。在这一系列化合物中,咪唑上取代基的位置和性质极大地影响了抗炎活性。3-烷基或3-苄基取代导致强效活性,但1-取代则不然。苄基的微小修饰降低或消除了活性。对构效关系的详细研究产生了3-苄基-5-苯基-3H-咪唑并[4,5-c][1,8]萘啶-4(5H)-酮(22),其在角叉菜胶、酵母聚糖和反向被动Arthus反应诱导的大鼠爪肿胀中表现出强效口服抗炎活性(ED40分别为5.3、0.37mg/kg,ED50为0.47mg/kg)。22的这种广泛活性类似于糖皮质激素。化合物22不影响CO和5-LO酶的活性以及各种配体的受体结合。作为作用机制之一,推测其诱导糖皮质激素的释放。这些结果表明22代表了一类新型抗炎剂。